GlassScriptPhysician profile
Bryce B Buente
NPI 1912534959
$2,066.33
in general payments reported to CMS, 2019-2025
22 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $312 · 2024: $729 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.86 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $337.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $160.86 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $136.01 | 2023-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Amgen INC. | $129.28 | 2023-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $120.68 | 2023-2025 | Airsupra, Breztri |
| Mylan Specialty L.P. | $95.84 | 2024 | Yupelri |
| Viatris Specialty LLC | $91.78 | 2025 | Yupelri |
| Exact Sciences Corporation | $61.37 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $51.09 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $25.11 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $25.07 | 2025 | |
| Axsome Therapeutics, INC. | $21.18 | 2023 | Auvelity |
| Astellas Pharma US INC | $18.06 | 2024 | Veozah |
| Tris Pharma INC | $17.69 | 2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.15 | 2025 | Xifaxan |
| Halozyme INC | $16.02 | 2023 | |
| Currax Pharmaceuticals LLC | $15.06 | 2025 | Contrave |
| Collegium Pharmaceutical, INC. | $14.72 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $13.58 | 2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $13.18 | 2023 | Unithroid |
| Mayne Pharma Commercial LLC | $10.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Buente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.